UroGen Pharma Ltd. (URGN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 41.09 |
| Open | 41.04 |
| Day High | 41.11 |
| Day Low | 38.02 |
| 52-Week High | 43.93 |
| 52-Week Low | 15.86 |
| Volume | 814,692 |
| Average Volume | 786,396 |
| Market Cap | 1.86B |
| PE | -13.91 |
| EPS | -2.75 |
| Moving Average 50 Days | 34.75 |
| Moving Average 200 Days | 25.09 |
| Change | -2.85 |
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
GlobeNewswire Inc.
Mar 02, 2026 12:55 PM GMT
Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded at closing to refinance the existing $125 million debt facility and provide additional non-di
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
GlobeNewswire Inc.
Feb 27, 2026 1:30 PM GMT
• EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Lt
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 9:05 PM GMT
PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management wi